{"drugs":["Eflornithine Hydrochloride","Vaniqa"],"mono":{"0":{"id":"923382-s-0","title":"Generic Names","mono":"Eflornithine Hydrochloride"},"1":{"id":"923382-s-1","title":"Dosing and Indications","sub":[{"id":"923382-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Female hirsutism, Facial:<\/b> apply 13.9% cream as a thin layer to affected areas of the face twice daily, application should be at least 8 hours apart and cream should remain on skin for at least 4 hours<\/li><li><b>Trypanosomiasis:<\/b> 100 mg\/kg IV over at least 45 min every 6 h for 14 days<\/li><\/ul>"},{"id":"923382-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy has not been established in pediatric patients<\/li><li><b>Female hirsutism, Facial:<\/b> (12 y and older) apply 13.9% cream as a thin layer to affected areas of the face twice daily, application should be at least 8 hours apart and cream should remain on skin for at least 4 hours<\/li><\/ul>"},{"id":"923382-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> slower excretion of eflornithine occurs with renal impairment; dosing should be adjusted based on CrCl, however, specific dosing recommendations are not available"},{"id":"923382-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Female hirsutism, Facial<\/li><li>Trypanosomiasis<\/li><\/ul>"}]},"3":{"id":"923382-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923382-s-3-9","title":"Contraindications","mono":"hypersensitivity to eflornithine<br\/>"},{"id":"923382-s-3-10","title":"Precautions","mono":"pre-existing bone marrow suppression or hematologic abnormalities<br\/>"},{"id":"923382-s-3-11","title":"Pregnancy Category","mono":"Eflornithine: C (FDA)<br\/>"},{"id":"923382-s-3-12","title":"Breast Feeding","mono":"<ul><li>Eflornithine: WHO: WHO documentation states insufficient data.<\/li><li>Eflornithine: Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"4":{"id":"923382-s-4","title":"Drug Interactions","sub":[{"id":"923382-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"923382-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"}]},"5":{"id":"923382-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Acne, With topical cream, Stinging of skin, Topical cream<br\/><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Myelosuppression, IV dose form (14-55%), Thrombocytopenia, IV dose form (14-48%)<\/li><li><b>Neurologic:<\/b>Seizure, IV dose form (8%)<\/li><li><b>Otic:<\/b>Ototoxicity, IV dose form<\/li><\/ul>"},"6":{"id":"923382-s-6","title":"Drug Name Info","sub":{"0":{"id":"923382-s-6-17","title":"US Trade Names","mono":"Vaniqa<br\/>"},"2":{"id":"923382-s-6-19","title":"Class","mono":"<ul><li>Hair Growth Retardant<\/li><li>Ornithine Decarboxylase Inhibitor<\/li><\/ul>"},"3":{"id":"923382-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923382-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923382-s-7","title":"Mechanism Of Action","mono":"Eflornithine hydrochloride is thought to irreversibly inhibits skin ornithine decarboxylase (ODC). This activity suppresses cell division and synthesis, which affect hair growth.<br\/>"},"8":{"id":"923382-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"923382-s-8-23","title":"Absorption","mono":"Bioavailability: less than 1% <br\/>"},"2":{"id":"923382-s-8-25","title":"Metabolism","mono":"Not known to be metabolized <br\/>"},"3":{"id":"923382-s-8-26","title":"Excretion","mono":"Renal: unchanged <br\/>"},"4":{"id":"923382-s-8-27","title":"Elimination Half Life","mono":"Approximately 8 h <br\/>"}}},"9":{"id":"923382-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>apply thin layer to affected areas of face and adjacent involved areas under chin; rub in thoroughly; apply at least 5 minutes after hair removal<\/li><li>do not wash treated area for at least 4 h<\/li><li>may apply cosmetics or sunscreens after cream has dried<\/li><\/ul>"},"10":{"id":"923382-s-10","title":"Monitoring","mono":"reduced facial hair<br\/>"},"11":{"id":"923382-s-11","title":"How Supplied","mono":"<b>Vaniqa<\/b><br\/>Topical Cream: 13.9 %<br\/>"},"13":{"id":"923382-s-13","title":"Clinical Teaching","mono":"<ul><li>The cream may cause acne or stinging.<\/li><li>Advise patient it may be several weeks before improvement is seen. However, drug should not be used longer than 6 mo if it does not appear to be working.<\/li><li>Inform patient that the effects of this drug are not permanent. Once discontinued, hair growth will likely return.<\/li><li>Patient should apply drug at least 5 min after hair removal and should not wash treated area for at least 4 h after administration.<\/li><li>Patient may apply cosmetics or sunscreens after the cream has dried.<\/li><li>If a dose has been missed, apply as soon as possible and then wait at least  8 h until the next application.<\/li><\/ul>"}}}